Proceeds to Fund Programs Addressing Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, April 28, 2021 —...
Read MoreNorfolk, VA, April 9, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive...
Read MoreNorfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...
Read MoreNorfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...
Read MoreNorfolk, VA, July 28, 2020 — ReAlta Life Sciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has...
Read MoreNorfolk, VA, June 29, 2020 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer,...
Read MoreNorfolk, VA, April 21, 2020 — ReAlta Life Sciences, Inc., today announced that it has successfully closed an oversubscribed Series A2...
Read MoreNorfolk, VA, April 9, 2020 — ReAlta Life Sciences, Inc., a biotech company dedicated to harnessing the power of the immune...
Read MoreNorfolk, VA, March 10, 2020 — ReAlta Life Sciences, Inc., a biotechnology company dedicated to harnessing the power of the immune...
Read More